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Introduction
Sepsis is the primary cause of death in the intensive care 
unit [1], and more than 35% of patients are admitted with 
sepsis or develop it during their intensive care unit stay. 
Hospital mortality rates are 27%, reaching 54% in the 
case of septic shock [2].
Extracorporeal blood puriﬁ  cation therapies have been 
proposed to improve outcomes for patients with sepsis. 
Th   ese therapies are based on the principle that removal 
of inﬂ  ammatory mediators or bacterial toxins (or both) 
from the blood will favorably modulate the host inﬂ  am-
ma  tory response. Recently, signiﬁ  cant technological pro-
gress has greatly broadened the spectrum of techniques 
available for blood puriﬁ  cation. Indeed, promising results 
have been reported with high-volume hemoﬁ  ltration 
(HVHF), cascade hemoﬁ  ltration, hemoadsorption, plasma-
pheresis, coupled plasma ﬁ   ltration adsorption (CPFA), 
high-adsorption hemoﬁ  ltration, and high-cutoﬀ   (HCO) 
hemodialysis/hemoﬁ  ltration. However, these techniques 
have not entered into mainstream clinical practice 
around the world.
Th   is overview has three aims. First, we will report on 
the latest advances in blood puriﬁ  cation for sepsis. Th  en, 
we will brieﬂ  y describe each therapy and explain how 
they work and discuss how they relate to current 
concepts of disease. Finally, we will review the current 
evidence from the medical literature, highlighting the 
most important studies related to each therapy. To select 
articles from medical literature, we conducted a syste-
matic review of the MEDLINE database using PubMed 
with the following search terms: blood puriﬁ  cation, high-
volume hemoﬁ   ltration, sepsis, hemoadsorption, high-
cutoﬀ   membranes, and coupled plasma ﬁ  ltration adsorp-
tion. Th   e search included experimental and clinical studies.
Concept of blood purifi  cation
Systemic inﬂ  ammatory states such as severe sepsis and 
septic shock result in immunologic disturbances with the 
release of numerous inﬂ  ammatory mediators. Th  e sys-
temic inﬂ  ammatory response, though a result of innate 
immunity, can become deleterious when excessive or 
uncontrolled, leading to the development of multi-organ 
failure syndrome and death. At least two mecha  nisms are 
identiﬁ  ed to explain the potential harmful eﬀ  ects of this 
host inﬂ  ammatory response: cyto  kines have the capacity 
to damage the cells (cytotoxic eﬀ   ects) [3], and the 
prolonged release of inﬂ   ammatory mediators leads to 
severely impaired immunity [4]. Th  is ‘immunoparalysis’ 
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severe secondary nosocomial infections. Secondary 
infections can be bacterial but also may be related to 
reactivation of dormant viruses [5,6].
Th   e overall concept of blood puriﬁ  cation is therefore to 
attenuate this overwhelming systemic expression of pro- 
and anti-inﬂ  ammatory mediators. Restoration of immune 
homeostasis is thought to be able to improve outcomes 
and survival. Multiple mediators are involved in this 
inﬂ  ammatory response [7], but past attempts to modulate 
it by targeting single components have failed, at least at 
the clinical phase [8]. Th   us, over time, the blood puri  ﬁ  -
cation concept and therapies have evolved toward the 
non-speciﬁ   c removal of a broad spectrum of inﬂ  am-
matory mediators, which can also include microbial toxins.
Recently, a number of theories to explain the eﬀ  ects of 
blood puriﬁ  cation have been proposed. First, Ronco and 
colleagues [9] hypothesized that eliminating the peaks of 
cytokine blood concentrations during the early phase of 
sepsis could stop the inﬂ  ammatory cascade, limit organ 
damage, and consequently decrease the incidence of 
multi-organ failure syndrome. Second, Honoré and 
Matson [10] proposed the ‘threshold immunomodulation 
hypothesis’, postulating that the cytokine removal from 
the blood compartment leads to the removal of cytokines 
located at the tissue level because of an equilibration of 
their concentrations between these two compartments. 
Th  is theory explains why numerous studies assessing 
blood puriﬁ  cation techniques found an improvement of 
outcomes with no modiﬁ  cation of cytokine blood con-
cen  trations as cytokines from the tissues replace those 
removed from the blood. Th   ird, Di Carlo and Alexander 
[11] proposed the ‘mediator delivery hypothesis’, in which 
HVHF is responsible for an increase of the lymphatic 
ﬂ  ow because of the high amounts of crystalloid ﬂ  uids 
used for replacement with this technique. Th   is leads to a 
signiﬁ   cant drag and displacement of inﬂ  ammatory 
media  tors to the blood compartment, making them 
available for removal [11].
Finally, Peng and colleagues [12] recently suggested 
that blood puriﬁ  cation therapies act at the inﬂ  ammatory 
cell level to restore the immune function through the 
regulation of monocytes, neutrophils, or even lympho-
cytes. Th   is theory is supported by recent studies [13,14]. 
Indeed, it has been reported that polymyxin B hemo-
adsorption could increase the expression of leukocyte 
surface markers such as HLA-DR [13]. Th  us, hemo-
adsorption would act as a ‘reprogrammation system’ for 
the leukocytes. However, the mechanism by which hemo-
adsorption stimulates HLA-DR expression remains 
unknown. If this ‘cellular level’ theory with immune 
response restoration is conﬁ  rmed, timing indications for 
blood puriﬁ  cation would need to be reconsidered since 
optimal timing for initiating a blood puriﬁ  cation therapy 
would not be only in the early phase of septic shock as it 
is suggested today. Furthermore, a novel component of 
this hypothesis is that, by removing mediators from the 
plasma in the setting of systemic inﬂ  ammation, one can 
restore the concentration gradient from plasma to 
infected tissues [12]. Th   is gradient has signiﬁ  cant eﬀ  ects 
on leukocyte traﬃ     cking and bacterial clearance [14]. 
Th   us, the ‘cytokinetic model’ may be more relevant than 
cytotoxic models to explain the association between high 
cytokine levels and mortality (Figure 1).
High-volume hemofi  ltration
By increasing plasma water exchanges, HVHF appears to 
be an attractive therapy to remove a signiﬁ  cant amount 
of inﬂ  ammatory mediators from the plasma. First, these 
circulating molecules are predominately water-soluble 
and convection carries both plasma water and solutes 
across a semi-permeable membrane along a hydrostatic 
pressure gradient. Second, most inﬂ  ammatory mediators 
are so-called middle-molecular-weight molecules with a 
wide range of mass (from 5 to 60 kDa) and convection is 
far more eﬀ   ective than diﬀ   usion in removing middle 
molecules [15,16]. Th  ird, depending on their composi-
tion, most hemoﬁ   ltration membranes also have some 
adsorptive properties. Th  e  ultraﬁ  ltrate contains the mole-
cules from the plasma which are able to cross the 
membrane (molecular weight below the membrane cut-
oﬀ  ), and adsorption allows the removal of some other 
molecules with a molecular weight higher than the 
membrane cutoﬀ  .
HVHF is not well deﬁ   ned in the medical literature. 
Recently, Honoré and colleagues [17] convened a con  sen-
sus conference to clarify the deﬁ  nition of HVHF. Th  ey 
agreed that HVHF includes continuous high-volume 
treatment of 50 to 70 mL/kg per hour 24 hours a day and 
intermittent HVHF with brief, very-high-volume treat-
ment at 100 to 120 mL/kg per hour for a short period of 4 
to 8 hours, followed by conventional continu  ous veno-
venous hemoﬁ   ltration (CVVH). Th  is latter strategy is 
also called ‘pulse HVHF’ [18]. However, for experts from 
the Acute Dialysis Quality Initiative work  group, greater 
than 35  mL/kg per hour is already con  sidered HVHF 
[19]. Indeed, given that ‘renal dose’ hemo  ﬁ  ltration for 
acute kidney injury has been standardized at 25 to 
30 mL/kg per hour (see reference [20] for justiﬁ    cation), 
deﬁ  ning HVHF at greater than 35 mL/kg per hour seems 
reasonable.
Many animal studies have been performed to assess 
HVHF, especially in the 1990s, when HVHF was still very 
experimental in humans. Grootendorst and colleagues 
[21] reported an improvement in cardiac performance in 
pigs with endotoxin-induced shock when HVHF was 
applied. Th   e authors hypothesized that some vasoactive 
mediators, responsible for the myocardial depression, 
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recently suggested a positive eﬀ  ect on the myocardial 
mitochondrial dysfunction [22], the pathophysiologic 
explanation of the hemodynamic improvement with 
HVHF remains unclear [23]. In septic dogs, Bellomo and 
colleagues [24] also found that HVHF improved hemo-
dynamic parameters compared with a sham circuit with 
no hemoﬁ   lter. Furthermore, some animal studies 
assessed HVHF by looking at ultraﬁ  ltrate obtained from 
either healthy donor or septic donor animals and infused 
into a healthy acceptor animal. Th  e ability of HVHF to 
remove toxic mediators is suggested when ultraﬁ  ltrate 
obtained from septic animals leads to hemodynamic 
distur  bances or even death in healthy animals. In a 
prospective randomized controlled study including 65 
septic pigs, Lee and colleagues [25] reported an increase 
survival time in ﬁ  ltered animals compared with matched 
non-ﬁ   ltered ones. Increments in survival time even 
increased directly with ﬁ   ltration fraction. Moreover, 
ultraﬁ   ltrate concentrate obtained from septic pigs 
produced death in healthy ones whereas the infusion of 
‘clean’ ultraﬁ  ltrate concentrate produced no response.
Numerous human studies have shown beneﬁ  cial 
hemodynamic eﬀ  ects of HVHF. In a randomized cross-
over study of 11 patients with septic shock and multi-
organ failure, an 8-hour period of HVHF (6 L/hour) was 
associated with a greater reduction in norepinephrine 
requirements in comparison with a similar period of 
CVVH (1 L/hour) [26]. Reduction of vasopressor require-
ments with HVHF was also found more recently in a pilot 
randomized study comparing CVVH at 65 mL/kg per 
hour versus 35 mL/kg per hour in 20 septic shock 
patients with acute kidney injury [27]. Large randomized 
controlled studies of HVHF in septic shock which use 
mortality as the primary outcome are lacking. One such 
study, known as the IVOIRE (High Volume in Intensive 
Care) study, which compares 70 mL/kg per hour versus 
35  mL/kg per hour, is currently ongoing in Europe. 
Although results from this study have not yet been 
released, the investigators have reported that the enroll-
ment process was very slow and therefore the number of 
patients included is likely to be less than 150, making 
conclusions regarding mortality diﬃ   cult  to  establish. 
Th   us, the only available studies regarding mortality have 
Figure 1. The ‘cytokinetic model’. Blood purifi  cation therapies increase the cytokine/chemokine concentration gradient from plasma to infected 
tissue by removing those infl  ammatory mediators from the blood compartment. Consequently, leukocyte traffi   cking is driven toward the nidus of 
infection, allowing the increase of local bacterial clearance. CPFA, coupled plasma fi  ltration adsorption; HVHF, high-volume hemofi  ltration.
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the patients’ severity scores at admission. Th  ough  uncon-
trolled, at least six studies have found signiﬁ  cant (and 
sometimes spectacular) reductions in mortality rate with 
HVHF compared with predicted mortality [28-33]. 
Honoré and colleagues [29] reported a reduction of the 
mortality rate from 79% (expected mortality based on 
APACHE II [Acute Physiology and Chronic Health 
Evalua  tion II] score and SAPS II [Simpliﬁ  ed  Acute 
Physiology Score II]) to 55%. Several years later, Joannes-
Boyau and colleagues [30] obtained a similar result with a 
predicted 28-day mortality of 70% and an observed 
mortality of 46% in a study assessing the eﬀ  ect of 40 to 
60 mL/kg per hour maintained for 96 hours in patients 
with septic shock. In patients without sepsis but with 
systemic inﬂ  ammation, the eﬀ  ect of HVHF on mortality 
was evaluated in two randomized controlled trials 
[34,35]. In 61 resuscitated cardiac arrest patients, very-
high-volume hemoﬁ  ltration (200 mL/kg per hour during 
8 hours) was associated with improved 6-month survival 
and a decreased risk of death from early intractable shock 
[35]. Th   e most important recent studies assessing 
mortality with HVHF as a blood puriﬁ  cation therapy are 
summarized in Table  1. Unlike HVHF, standard ‘renal 
dose’ continuous renal replacement therapy (CRRT) 
appears to be ineﬀ   ective as an immune modulating 
therapy. Like Cole and colleagues [36] in 2002, Payen and 
colleagues [37] found no diﬀ  erence (and even a trend 
toward worse outcomes) between septic shock patients 
who did not have acute kidney injury and who underwent 
CVVH (25 mL/kg per hour for a 96-hour period) at the 
early phase of sepsis and those who were managed 
conventionally.
HVHF has important limitations such as a theoretical 
depletion of low-molecular-weight molecules (nutrients, 
vitamins, trace elements, and drugs such as antibiotics), 
an elevated cost due mainly to the requirement of large 
replacement ﬂ  uid amounts, and a high nursing workload 
[38,39]. Cascade hemoﬁ  ltration was recently developed 
to limit some of these drawbacks [40]. It allows appli-
cation of HVHF select  ively on middle-molecular-weight 
molecules with a low replacement ﬂ  uid ﬂ  ow rate because 
of a particular circuit that combines two hemoﬁ  ltration 
membranes having diﬀ  erent cutoﬀ  s (Figure 2).
Hemoadsorption
Hemoadsorption places sorbents in direct contact with 
blood via an extracorporeal circuit. Th  e sorbent attracts 
solutes through hydrophobic interactions, ionic attrac  tion, 
hydrogen bonding, and van der Waals interactions [41]. 
Until recently, poor biocompatibility has been the main 
clinical limitation of hemoadsorption, as evidenced by 
severe thrombocytopenia and leukopenia [41]. Th  e  interest-
ing feature of hemoadsorption is its high-molecular-weight 
adsorption potential, allowing it to target large molecules, 
exceeding the cutoﬀ   of conventional synthetic high-ﬂ  ux 
hemoﬁ  lters.
Polymyxin B is a cyclic basic polypeptide that disrupts 
the permeability of the cell membrane of Gram-negative 
bacteria. It was developed as an antibiotic but its severe 
renal toxicity precludes systemic use. However, poly-
myxin B-immobilized polystyrene-derived ﬁ  bers  have 
been developed for use in extracoporeal therapy as a 
means to remove endotoxin from the blood. Th  ough  still 
under evaluation in Europe and the US, polymyxin B 
hemoadsorption (Toraymyxin; Toray Industries, Inc., 
Tokyo, Japan) is widely used in Japan as a blood puriﬁ  -
cation therapy and is covered by the Japanese national 
health insurance [42]. Th  e EUPHAS (Early Use of 
Polymyxin B Hemoperfusion in Abdominal Sepsis) study 
was a prospective, multicenter randomized controlled 
study that was performed in 10 Italian intensive care 
units [43]. Sixty-four patients with severe sepsis or septic 
shock were randomly assigned to one of two groups 
(either conventional therapy or conventional therapy 
along with two sessions of polymyxin B hemoadsorption) 
within the 6 hours following emergency surgery for intra-
abdominal infection. Hemodynamics, the PaO2/FiO2 
(arterial partial pressure of oxygen/fraction of inspired 
oxygen) ratio, and the SOFA (Sequential Organ Failure 
Assessment) score of patients from the hemoadsorption 
group improved within 72 hours, whereas the conven-
tional group did not. Th  e main result (though not the 
primary outcome) of this study was the 28-day mortality 
rate, which was drastically reduced to 32% in the hemo-
adsorption group compared with 53% in the control 
group (P = 0.03). However, the conclusions of this study 
should be taken with caution. Indeed, although mortality 
was only a secondary endpoint, the study was prema-
turely stopped because it was judged to be unethical to 
deprive patients of hemoadsorption. Th   e decision to halt 
the study seems extremely debatable because it was based 
upon a secondary analysis of an underpowered study and 
a diﬀ   erent outcome in a single patient would have 
abolished the statistical diﬀ   erence in mortality [44]. 
Moreover, the fact that the study was controlled is also 
debatable since hemodynamic and respiratory para-
meters were only analyzed independently within each 
group, comparing 72-hour to baseline levels. No statis-
tical comparison was performed between the two groups 
at 72 hours. No statistical comparison was performed 
between the two groups at 72 hours.
Other trials showed interesting results with polymyxin 
B hemoadsorption. Vincent and colleagues [45] con-
ducted a multicenter randomized controlled study that 
enrolled 36 postsurgical patients with septic shock. Nine-
teen patients were allocated to standard treatment, and 
17 were given an additional polymyxin B hemoadsorption 
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not diﬀ  erent between the two groups within the 24 hours 
following the start of treatment. However, patients 
treated with hemoadsorption had a marked improvement 
in hemodynamics and oxygen transport function, and the 
need for CRRT after the study was less important in the 
hemoadsorption group. Th  ese  beneﬁ  cial eﬀ  ects were also 
reported in a systematic review of 28 publications (1,425 
patients) [46]. Indeed, although Cruz and colleagues [46] 
highlighted the suboptimal quality of the studies, 
favorable eﬀ  ects regarding blood pressure, vasopressor 
require  ment, gas exchanges, and even mortality were 
Table 1. Summary of recent human studies that assessed the eff  ects of high-volume hemofi  ltration as a blood 
purifi  cation technique on hemodynamics and survival
       Dose,    Improved  Improved 
   Number  of    mL/kg  hemodynamics  survival  P value
Study  Design  patients  Clinical setting  per hour  with HVHF  with HVHF  (survival)
Honoré, et al.   Prospective,   20  Refractory septic  115  Yes  Yes.   <0.05
[29] 2000   cohort,     shock     28-day survival: 21% (expected) 
  uncontrolled          to 45% (observed) 
Cole, et al.   Randomized,   11  Septic shock with  6,000 mL/hour  Yes  Not assessed  N/A
[26] 2001   crossover   multi-organ failure
Joannes-Boyau,   Prospective,   24  Septic shock   40-60  Yes  Yes.   <0.075
et al. [30] 2004   cohort,           28-day survival: 30% (expected) 
  uncontrolled           to 54% (observed) 
Laurent, et al.   RCT  61  Resuscitated   200  Yes  Yes.   0.026
[35] 2005       cardiac arrest     Six-month survival: 21% to 45%
Jiang, et al.   RCT  37  Severe acute   4,000 mL/hour  Yes  Yes.   <0.01
[34] 2005       pancreatitis     14-day survival: 68.4% to 94.4%
Ratanarat, et al.   Prospective,   15  Severe sepsis  85 (pulse HVHF)  Yes  Yes.   N/A
[33] 2005   cohort,           28-day survival: 30% (expected) 
 uncontrolled        to 53% (observed)
Piccinni, et al.   Retrospective,   80  Septic shock  45  Yes  Yes.  
[32] 2006   uncontrolled       28-day survival: 27.5% to 55%  0.005
Cornejo, et al.   Prospective,   20  Refractory septic  100  Yes  Yes.   <0.03
[28] 2006   cohort,     shock      Hospital survival: 37% (expected) 
 uncontrolled        to 60% (observed)  
Boussekey, et al.   RCT  20  Septic shock  65  Yes  No  0.65
[27] 2008 
Zhu, et al.   Retrospective  63  Severe acute  60-80  No  Yes.   0.014
[77] 2009       pancreatitis      28-day survival: 65.5% to 91.2%
IVOIRE study,   RCT  Approximately   Septic shock  70  Not  Not  Not
ongoing   150      reported  reported  reported
HVHF, high-volume hemofi  ltration; IVOIRE, High Volume in Intensive Care; N/A, not applicable; RCT, randomized controlled trial.
Figure 2. Cascade hemofi  ltration circuit.
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further rigorous studies of this therapy. Two large 
multicenter studies, similar to the EUPHAS study, were 
expected to be started in the US and Europe in 2010.
Th   e CytoSorb™ technology (CytoSorbents Corporation, 
Monmouth Junction, NJ, USA) is composed of cartridges 
containing biocompatible polystyrene divinyl benzene 
copolymer beads. Th   is technology does not target 
endotoxin but has been shown to result in rapid in vitro 
and in vivo elimination of several key cytokines [47]. 
Recently, 33 septic rats were randomly assigned to receive 
either hemoadsorption or sham treatment for 3 hours 
[48]. Cytokine concentrations were lower in the hemo-
adsorption group at the end of the treatment and this 
diﬀ  erence lasted 6 hours after treatment. Blood pressure 
of the rats from the hemoadsorption group was higher 
than that of the sham group. Finally, the overall survival 
rate (deﬁ  ned at 12 hours after randomization) was also 
signiﬁ  cantly greater in the hemoadsorption group (11/17 
versus 2/16; P <0.01).
Th  e resin referred to by its manufacturer as “CTR 
resin” (Kaneka Corporation, Osaka, Japan) is an adsor-
bent composed of porous cellu  lose beads. Taniguchi and 
colleagues [49] reported that CTR eﬀ  ectively adsorbed 
small- to middle-sized proteins such as cytokines, entero-
toxins, and toxic shock syn  drome toxin-1 in vitro. Addi-
tion  ally, in an endotoxemic rat model, hemoadsorption 
with CTR dramatically reduced the mortality rate 8 hours 
after endotoxin injection (14% versus 92% for endo  toxe-
mia alone) [49]. Interestingly, the same authors further 
demon  strated in rats the dose-related eﬀ  ects  of 
hemoadsorption with CTR on mortality [50].
Plasmapheresis and coupled plasma fi  ltration 
adsorption
Only very limited data are available in the medical litera-
ture regarding plasmapheresis, plasma exchanges, and 
related techniques for this indication [51-55]. Never-
theless, it has been suggested that these therapies might 
be beneﬁ  cial, especially for patients with Gram-negative 
sepsis [52,54,56,57] and when implemented as early as 
possible [58]. Additional studies are therefore warranted 
to better assess these therapies for blood puriﬁ  cation 
[59].
CPFA ﬁ  rst separates plasma from the blood by means 
of a plasma ﬁ  lter. Th  e plasma then circulates through a 
sorbent, allowing inﬂ  ammatory mediator adsorption, and 
ﬁ  nally returns to the blood, where a second blood ﬁ  lter is 
used for renal support (hemoﬁ  ltration, hemodialysis, or 
hemodiaﬁ   ltration) (Figure 3). Performing adsorption 
with plasma, rather than with blood, avoids coagulation 
issues, platelet aggregation, and hemolysis and allows the 
use of a low ﬂ   ow rate, extending the time of contact 
between the inﬂ   ammatory mediators and the sorbent 
and consequently maximizing their adsorption.
Several studies have demonstrated the safety and the 
eﬀ  ectiveness of CPFA for removing inﬂ  ammatory media-
tors from the circulation [60,61]. Moreover, CPFA was 
able to increase the survival of a rabbit model of endo-
toxic shock and to improve hemodynamics and the 
pulmonary function of patients with septic shock [62,63]. 
Recently, CPFA was compared with other extracorporeal 
blood puriﬁ   cation techniques. In a small pilot study, 
Lentini and colleagues [64] reported no diﬀ  erence  in 
hemodynamic eﬀ  ects between pulse HVHF and CPFA in 
patients with septic shock. In pigs with hyperdynamic 
septic shock, continuous hemoﬁ   ltration, unlike CPFA, 
was able to remove some inﬂ  ammatory  mediators 
involved in delayed cardiac repolarization [65]. Con-
versely, Ronco and colleagues [61] reported in patients 
with septic shock that CPFA combined with hemodialysis 
was associated with greater improved hemodynamics 
compared with continuous hemodiaﬁ  ltration.  Th  e 
authors hypothesized that this result could be due to the 
ability of CPFA to restore leukocyte responsiveness to 
lipo  polysaccharide. Interestingly, eﬀ   ects of CPFA on 
immune function were also shown by Mao and colleagues 
[66] in a small crossover study comparing CPFA with 
HVHF in septic patients with multiple organ dysfunction 
syndrome. HLA-DR expression increased after CPFA but 
Figure 3. Coupled plasma fi  ltration adsorption circuit.
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taneous and lipopolysaccharide-induced tumor necrosis 
factor production increased over time with CPFA but did 
not change with HVHF. Th   e authors therefore suggested 
that CPFA was superior to HVHF in restoring leukocyte 
responsiveness.
High-adsorption hemofi  ltration and high-cutoff   
membranes
Other approaches proposed for blood puriﬁ  cation 
therapies consist of optimizing the performances of the 
hemoﬁ  lters regarding cytokine or endotoxin removal (or 
both) by manipulating their composition or structure. 
High-adsorption hemoﬁ  ltration is a technique whereby 
the adsorption properties of a hemoﬁ  lter are enhanced. 
Positive hemodynamic eﬀ   ects of a polyacrylonitrile 
hemoﬁ  ltration membrane having endotoxin adsorption 
properties were recently reported in septic pigs [67]. Th  e 
membrane surface polarity was modiﬁ  ed by adjunction 
of a polyethylenimine coating, a positively charged poly-
mer, allowing it to catch negatively charged endotoxins 
via surface adsorption. Th  is study highlights another 
potentially important aspect of blood puriﬁ  cation for the 
future: the synergy between diﬀ  erent blood puriﬁ  cation 
mechanisms (HVHF + high adsorption) [67,68]. In the 
same line, other models in which HVHF and high-
permeability hemoﬁ   ltration work synergistically have 
shown promising results [69].
Th   e use of HCO membranes represents another logical 
strategy to increase mediator removal. When the mem-
brane pore size is increased from 0.01 to 0.02 μm 
(Figure  4), the spectrum of molecules aﬀ  ected by the 
therapy is signiﬁ  cantly broadened [70]. In experimental 
models of sepsis, HCO membranes improve hemo-
dynamics and prolong survival [71]. In patients with 
sepsis-induced acute kidney injury, Morgera and 
colleagues [72] reported a reduction in vasopressor 
require  ments with the use of HCO hemoﬁ  ltration and 
not with conventional CVVH. Additionally, cytokine 
clear  ance rates were signiﬁ   cantly higher in the HCO 
hemo ﬁ   ltration group. In another randomized study, 
HCO hemoﬁ  ltration restored the monocyte proliferation 
Figure 4. Electronic microscopy images of the internal surface of diff  erent fi  lters.
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immunomodulatory mediators [73]. However, the use of 
HCO hemoﬁ  ltration has been challenged by the albumin 
loss, which can be up to 15 g per 4-hour session [74]. 
Consequently, HCO membranes are now proposed for 
use with hemodialysis. Indeed, the use of diﬀ  usion rather 
than convection is suggested to reduce the albumin loss 
without signiﬁ   cantly impacting cytokine clearances, 
especially in cases of elevated dialysate ﬂ  ow rates [74]. 
Haase and colleagues [75] showed that HCO hemo-
dialysis was more eﬃ   cient than standard hemo  dialysis in 
regard to diﬀ   usive cytokine clearances. While some 
decreases in plasma cytokine levels were even reported 
after only 4 hours of treatment, the albumin loss was 
limited and plasma albumin concentrations remained 
stable. Conversely, Lee and colleagues [76] recently 
highlighted reductions in serum albumin levels after 
HCO hemodialysis sessions, leaving this question open 
to further clinical investigation. To address this issue, 
membrane parameters and aspects other than the type of 
modality (diﬀ   usion versus convection) – for example, 
membrane homogeneity in terms of pore size, membrane 
surface, the use of super-high-ﬂ  ux hemoﬁ  lters that have a 
slightly lower cutoﬀ   , and the use of the association 
HVHF-high permeability – certainly need to be taken 
into account [69]. Finally, it should be mentioned that the 
medical literature regarding HCO membranes contains 
signiﬁ  cant heterogeneity due to diﬀ  erences in terms of 
type of HCO membrane (cutoﬀ   points, surface area, and 
composition), modality used, and type of cytokines 
measured, making conclusions regarding this strategy 
diﬃ   cult to establish.
Conclusions
Considerable work remains in order to ﬁ  nd and optimize 
the best blood puriﬁ   cation strategy for treatment of 
sepsis. A better understanding of how these therapies 
work by modulating the cytotoxic and cytokinetic eﬀ  ects 
of inﬂ   ammatory mediators is essential. Convection, 
diﬀ  usion, and adsorption should probably not be seen as 
competitive mechanisms for blood puriﬁ  cation  but 
rather as complementary ones. Many experimental and 
clinical studies have reported promising results showing 
that blood puriﬁ   cation therapies are well tolerated, 
eﬀ   ective in clearing inﬂ   ammatory mediators or endo-
toxins (or both) from the plasma, and responsible for an 
improvement of diﬀ  erent physiologic parameters (hemo-
dynamics and oxygenation). However, important ques-
tions, including timing, duration, and frequency of these 
therapies in the clinical setting, remain unanswered. 
Large multicenter trials evaluating the ability of these 
therapies to improve clinical outcomes (that is, mortality 
or organ failure), rather than focusing on surrogate 
markers such as plasma mediator clearance or transient 
improvement in physiologic variables, are required to 
deﬁ   ne the precise role of blood puriﬁ   cation in the 
management of sepsis.
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